Evidence & regulatory context
- Mechanism
- EXACT ChEMBL match: 'Kollidon va 64' appears verbatim in the synonym list of COPOVIDONE CHEMBL2108242. max_phase -1 (unknown clinical phase), first_approval NULL, therapeutic_flag FALSE, dosed_ingredient FALSE, structure_type NONE (polymer, no defined structure recorded). get_mechanism was NOT called: copovidone is a pharmaceutical EXCIPIENT and vinylpyrrolidone-vinyl acetate copolymer with no curated molecular target, so calling it would only have returned an uninformative zero. moa_list and target are therefore intentionally empty.
- Target
- Not recorded
- Injury models
- TBI
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Preclinical/no trial
- ChEMBL max phase
- -1 / 4 (development scale, not regulatory approval)
- Synonyms
- Kollidon VA 64; Copovidone; Copovidone K28; Plasdone S630; NSC-114023; NSC-114024; NSC-114025; NSC-114026
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseTBIControlled cortical impactMaleIntravenous (comparator agents also given intracerebroventricularly)1 mmol/L, 500 microlitres1 h after controlled cortical impact
Model: Controlled cortical impact traumatic brain injury
Kollidon VA64 resealed injured cell membranes in vivo and significantly reduced acute cellular degeneration, chronic tissue damage, oedema, blood-brain barrier damage and motor deficits, although it did not rescue pulse-labelled propidium iodide positive cells from eventual death.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.78. Machine-extracted fields require source verification.
